


Azelastine hydrochloride

Cat. No.:	HY-B0462
CAS No.:	79307-93-0
Molecular Formula:	C ₂₂ H ₂₅ Cl ₂ N ₃ O
Molecular Weight:	418.36
Target:	Histamine Receptor; SARS-CoV
Pathway:	GPCR/G Protein; Immunology/Inflammation; Neuronal Signaling; Anti-infection
Storage:	4°C, sealed storage, away from moisture * In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)



SOLVENT & SOLUBILITY

In Vitro	DMSO : 50 mg/mL (119.51 mM; Need ultrasonic)					
	H ₂ O : 6.67 mg/mL (15.94 mM; Need ultrasonic)					
	Preparing Stock Solutions	Solvent	Mass	1 mg	5 mg	10 mg
		Concentration				
		1 mM		2.3903 mL	11.9514 mL	23.9029 mL
5 mM			0.4781 mL	2.3903 mL	4.7806 mL	
	10 mM		0.2390 mL	1.1951 mL	2.3903 mL	
Please refer to the solubility information to select the appropriate solvent.						
In Vivo	1. Add each solvent one by one: 10% DMSO >> 40% PEG300 >> 5% Tween-80 >> 45% saline Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution					
	2. Add each solvent one by one: 10% DMSO >> 90% (20% SBE-β-CD in saline) Solubility: ≥ 2.5 mg/mL (5.98 mM); Clear solution					

BIOLOGICAL ACTIVITY

Description	Azelastine hydrochloride, an antihistamine, is a potent and selective histamine 1 (H ₁) antagonist. Azelastine hydrochloride can be used for the research of allergic rhinitis, asthma, diabetic hyperlipidemic and SARS-CoV-2 ^{[1][2][3][4]} .
IC₅₀ & Target	H ₁ Receptor
In Vitro	Azelastine hydrochloride can significantly inhibit HNEpC proliferation, and therefore, be helpful in against airway remodeling ^[5] . MCE has not independently confirmed the accuracy of these methods. They are for reference only. Cell Proliferation Assay ^[5]

Cell Line:	Human nasal epithelial cells (HNEpC)
Concentration:	100 μ M, 400 μ M
Incubation Time:	21 days
Result:	Inhibited HNEpC growth.

Western Blot Analysis^[5]

Cell Line:	Human nasal epithelial cells (HNEpC)
Concentration:	100 μ M
Incubation Time:	7 days
Result:	Significantly up-regulated the H1R, M1R and M3R levels.

In Vivo

Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) significantly reduces blood glucose, HbA1c and serum alkaline phosphatase (ALP), osteocalcin and downregulates apolipoprotein B in diabetic hyperlipidemic rats model^[2].
 Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) improves the lipid profile (LDL-c decrease and HDL-c increase) in diabetic hyperlipidemic rats model^[2].
 Azelastine hydrochloride (4 mg/kg; p.o.; daily; for 8 weeks) attenuates calcium deposition and aortic calcification in diabetic hyperlipidemic rats model^[2].
 MCE has not independently confirmed the accuracy of these methods. They are for reference only.

Animal Model:	Male albino Wistar rats (150-170 g), diabetic hyperlipidemic rats model ^[2]
Dosage:	4 mg/kg
Administration:	Oral administration, daily, for 8 weeks
Result:	Ameliorated aortic calcification and increased apolipoprotein A expression along with a decline in apolipoprotein B.

REFERENCES

- [1]. Craig La Force. Review of the pharmacology, clinical efficacy, and safety of azelastine hydrochloride. *Expert Rev Clin Immunol*. 2005 Jul;1(2):191-201.
- [2]. Mohamed M Elseweidy, et al. Azelastine a potent antihistamine agent, as hypolipidemic and modulator for aortic calcification in diabetic hyperlipidemic rats model. *Arch Physiol Biochem*. 2020 Jul 2;1-8.
- [3]. Carlos D. Zappia, et al. Azelastine potentiates antiasthmatic dexamethasone effect on a murine asthma model. *Pharmacol Res Perspect*. 2019 Dec; 7(6): e00531.
- [4]. Li Yang, et al. Identification of SARS-CoV-2 entry inhibitors among already approved drugs. *Acta Pharmacol Sin*. 2020 Oct 28 : 1-7.
- [5]. Shao-Cheng Liu, et al. Effect of budesonide and azelastine on histamine signaling regulation in human nasal epithelial cells. *Eur Arch Otorhinolaryngol*. 2017 Feb;274(2):845-853.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA